Total Payments
$3,565
2024 Payments
$168.41
Companies
26
Transactions
222
Medicare Patients
1,908
Medicare Billing
$372,438
Payment Breakdown by Category
Food & Beverage$3,413 (95.7%)
Education$152.05 (4.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,413 | 213 | 95.7% |
| Education | $152.05 | 9 | 4.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $1,335 | 99 | $0 (2024) |
| GlaxoSmithKline, LLC. | $403.45 | 21 | $0 (2022) |
| Allergan Inc. | $296.80 | 20 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $204.72 | 14 | $0 (2020) |
| Astellas Pharma US Inc | $155.43 | 5 | $0 (2024) |
| Insmed, Inc. | $147.77 | 8 | $0 (2024) |
| ABBVIE INC. | $132.25 | 6 | $0 (2022) |
| Theravance Biopharma Inc. | $109.24 | 9 | $0 (2017) |
| Theratechnologies Inc. | $108.14 | 6 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $92.31 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $168.41 | 8 | Amgen Inc. ($55.90) |
| 2023 | $243.24 | 13 | Gilead Sciences, Inc. ($81.13) |
| 2022 | $431.50 | 21 | Gilead Sciences, Inc. ($152.40) |
| 2021 | $314.05 | 15 | AbbVie Inc. ($65.98) |
| 2020 | $277.81 | 17 | Gilead Sciences, Inc. ($140.18) |
| 2019 | $781.03 | 45 | Gilead Sciences, Inc. ($326.61) |
| 2018 | $772.55 | 57 | Gilead Sciences, Inc. ($322.87) |
| 2017 | $576.07 | 46 | Gilead Sciences Inc ($219.00) |
All Payment Transactions
222 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Inflammation | ||||||
| 10/31/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: Respiratory | ||||||
| 10/29/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: Infectious Diseases | ||||||
| 10/29/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Inflammation | ||||||
| 09/25/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Inflammation | ||||||
| 09/17/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: PULMONOLOGY | ||||||
| 04/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.03 | General |
| 03/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.90 | General |
| 11/28/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.63 | General |
| 11/17/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Respiratory | ||||||
| 11/08/2023 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $30.42 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 10/19/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.24 | General |
| 09/20/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.26 | General |
| 09/13/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $16.23 | General |
| Category: HFCWO | ||||||
| 05/16/2023 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 03/28/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $15.75 | General |
| Category: HFCWO | ||||||
| 02/23/2023 | Astellas Pharma US Inc | AmBisome (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Infectious Diseases | ||||||
| 02/01/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: Infectious Diseases | ||||||
| 02/01/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $9.37 | General |
| Category: HFCWO | ||||||
| 02/01/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $0.76 | General |
| Category: HFCWO | ||||||
| 02/01/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $0.29 | General |
| Category: HFCWO | ||||||
| 11/11/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.45 | General |
| 11/08/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $31.17 | General |
| Category: RESPIRATORY | ||||||
| 09/22/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.89 | General |
| 09/16/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.03 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 471 | 1,046 | $339,740 | $95,410 |
| 2022 | 6 | 501 | 938 | $319,145 | $87,215 |
| 2021 | 6 | 477 | 1,136 | $346,800 | $98,433 |
| 2020 | 5 | 459 | 1,070 | $322,505 | $91,379 |
Total Patients
1,908
Total Services
4,190
Medicare Billing
$372,438
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 141 | 540 | $121,500 | $35,571 | 29.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 188 | 215 | $125,775 | $30,523 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 130 | $39,000 | $12,292 | 31.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 122 | $36,600 | $12,082 | 33.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $12,870 | $3,852 | 29.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 14 | 17 | $3,995 | $1,089 | 27.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 207 | 230 | $134,550 | $35,909 | 26.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 143 | 442 | $99,450 | $25,553 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 80 | 128 | $38,400 | $12,431 | 32.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 91 | $27,300 | $8,115 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $14,040 | $3,791 | 27.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 18 | 23 | $5,405 | $1,416 | 26.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 138 | 629 | $133,200 | $36,816 | 27.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 176 | 199 | $116,415 | $32,186 | 27.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 37 | 132 | $39,600 | $11,680 | 29.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 73 | 115 | $34,500 | $11,339 | 32.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 25 | 25 | $14,625 | $4,168 | 28.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 28 | 36 | $8,460 | $2,244 | 26.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 148 | 571 | $119,910 | $34,241 | 28.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 177 | 197 | $115,245 | $32,219 | 28.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 33 | 154 | $46,200 | $13,450 | 29.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 84 | 128 | $38,400 | $10,185 | 26.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 17 | 20 | $2,750 | $1,284 | 46.7% |
About Dr. Brett Laurence, MD
Dr. Brett Laurence, MD is a Infectious Disease healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1356506372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brett Laurence, MD has received a total of $3,565 in payments from pharmaceutical and medical device companies, with $168.41 received in 2024. These payments were reported across 222 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($3,413).
As a Medicare-enrolled provider, Laurence has provided services to 1,908 Medicare beneficiaries, totaling 4,190 services with total Medicare billing of $372,438. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Sacramento, CA
- Active Since 07/21/2008
- Last Updated 10/19/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1356506372
Products in Payments
- AVYCAZ (Drug) $403.41
- Arikayce (Drug) $147.77
- TRELEGY ELLIPTA (Drug) $123.84
- NUCALA (Biological) $118.77
- ANORO (Drug) $118.52
- VIBATIV (Drug) $109.24
- EGRIFTA (Drug) $108.14
- ZERBAXA (Drug) $82.37
- Xerava (Drug) $60.85
- DIFICID (Drug) $59.52
- TEZSPIRE (Biological) $55.90
- STIOLTO RESPIMAT (Drug) $55.41
- XOLAIR (Drug) $55.24
- Cresemba (Drug) $48.47
- ISENTRESS (Drug) $45.50
- SMARTVEST (Device) $42.40
- BREO (Drug) $42.32
- XOLAIR (Biological) $37.07
- QVAR (Drug) $30.01
- CABENUVA (Biological) $26.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Sacramento
Claire Pomeroy, M.d., M.b.a, M.D., M.B.A
Infectious Disease — Payments: $2.5M
Infectious Disease $2.5M
Dr. David Asmuth, M.d, M.D
Infectious Disease — Payments: $424,974
Infectious Disease $424,974
Stuart Cohen, M.d, M.D
Infectious Disease — Payments: $15,711
Infectious Disease $15,711
Daniel Ikeda, M.d, M.D
Infectious Disease — Payments: $8,220
Infectious Disease $8,220
Dr. Richard Pollard, Md, MD
Infectious Disease — Payments: $4,763
Infectious Disease $4,763
Vinod Trivedi, Md, MD
Infectious Disease — Payments: $4,508
Infectious Disease $4,508